Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant

Vijay Shivaswamy, R. Brian Stevens, Ramona Zephier, Myhra Zephier, Junfeng Sun, Gerald Groggel, Judi Erickson, Jennifer Lynn Larsen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND. Patients with diabetes have been reported to have greater dyslipidemia after kidney transplant (KTX). Because postKTX management of diabetes has changed markedly since those reports, we hypothesized that lipids can be controlled as well in diabetic as in nondiabetic recipients. METHODS. We compared lipid levels up to 2 years after KTX (n=192) between diabetic and nondiabetic recipients. The cohort was subdivided into nondiabetic (nonDM-K; n=123), type 2 (DM2-K; n=33), or type 1 diabetes after KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22). RESULTS. Mean age and body mass index of DM2-K were greater than the others (P<0.01), and diabetes groups had a higher pretransplant A1C than nonDM-K (P<0.001). After KTX, lipid levels were not higher in diabetic than in nondiabetic recipients, and did not increase in any group. Total and low-density lipoprotein cholesterol levels decreased in DM1-K (P<0.001), high-density lipoprotein levels decreased in DM1-KP (P=0.02), and triglyceride levels were unchanged after KTX for all groups. A1C improved in DM1-K and DM1-KP (P<0.0001). There was less improvement in lipid levels with tacrolimus-sirolimus immunosuppression than with other steroid-containing regimens (P<0.05). CONCLUSIONS. Multiple mechanisms may contribute to better lipid levels in both groups as well as the lack of difference between diabetic and nondiabetic recipients compared with what has been reported previously: greater use of and more effective lipid-lowering agents, no significant weight gain, no difference in renal function between groups, and better control of glucose in the diabetic group. Thus, overall, lipids can be controlled as well in diabetic as in nondiabetic KTX recipients.

Original languageEnglish (US)
Pages (from-to)1270-1276
Number of pages7
JournalTransplantation
Volume85
Issue number9
DOIs
StatePublished - May 1 2008

Fingerprint

Dyslipidemias
Transplants
Kidney
Lipids
Tacrolimus
Sirolimus
HDL Lipoproteins
Type 1 Diabetes Mellitus
LDL Cholesterol
Immunosuppression
Weight Gain
Pancreas
Triglycerides
Body Mass Index
Steroids
Glucose
Control Groups

Keywords

  • Diabetes
  • Dyslipidemia
  • Kidney Transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant. / Shivaswamy, Vijay; Stevens, R. Brian; Zephier, Ramona; Zephier, Myhra; Sun, Junfeng; Groggel, Gerald; Erickson, Judi; Larsen, Jennifer Lynn.

In: Transplantation, Vol. 85, No. 9, 01.05.2008, p. 1270-1276.

Research output: Contribution to journalArticle

Shivaswamy, Vijay ; Stevens, R. Brian ; Zephier, Ramona ; Zephier, Myhra ; Sun, Junfeng ; Groggel, Gerald ; Erickson, Judi ; Larsen, Jennifer Lynn. / Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant. In: Transplantation. 2008 ; Vol. 85, No. 9. pp. 1270-1276.
@article{57d13d332a594794b9d801c7bad09858,
title = "Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant",
abstract = "BACKGROUND. Patients with diabetes have been reported to have greater dyslipidemia after kidney transplant (KTX). Because postKTX management of diabetes has changed markedly since those reports, we hypothesized that lipids can be controlled as well in diabetic as in nondiabetic recipients. METHODS. We compared lipid levels up to 2 years after KTX (n=192) between diabetic and nondiabetic recipients. The cohort was subdivided into nondiabetic (nonDM-K; n=123), type 2 (DM2-K; n=33), or type 1 diabetes after KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22). RESULTS. Mean age and body mass index of DM2-K were greater than the others (P<0.01), and diabetes groups had a higher pretransplant A1C than nonDM-K (P<0.001). After KTX, lipid levels were not higher in diabetic than in nondiabetic recipients, and did not increase in any group. Total and low-density lipoprotein cholesterol levels decreased in DM1-K (P<0.001), high-density lipoprotein levels decreased in DM1-KP (P=0.02), and triglyceride levels were unchanged after KTX for all groups. A1C improved in DM1-K and DM1-KP (P<0.0001). There was less improvement in lipid levels with tacrolimus-sirolimus immunosuppression than with other steroid-containing regimens (P<0.05). CONCLUSIONS. Multiple mechanisms may contribute to better lipid levels in both groups as well as the lack of difference between diabetic and nondiabetic recipients compared with what has been reported previously: greater use of and more effective lipid-lowering agents, no significant weight gain, no difference in renal function between groups, and better control of glucose in the diabetic group. Thus, overall, lipids can be controlled as well in diabetic as in nondiabetic KTX recipients.",
keywords = "Diabetes, Dyslipidemia, Kidney Transplant",
author = "Vijay Shivaswamy and Stevens, {R. Brian} and Ramona Zephier and Myhra Zephier and Junfeng Sun and Gerald Groggel and Judi Erickson and Larsen, {Jennifer Lynn}",
year = "2008",
month = "5",
day = "1",
doi = "10.1097/TP.0b013e31816de3F6",
language = "English (US)",
volume = "85",
pages = "1270--1276",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant

AU - Shivaswamy, Vijay

AU - Stevens, R. Brian

AU - Zephier, Ramona

AU - Zephier, Myhra

AU - Sun, Junfeng

AU - Groggel, Gerald

AU - Erickson, Judi

AU - Larsen, Jennifer Lynn

PY - 2008/5/1

Y1 - 2008/5/1

N2 - BACKGROUND. Patients with diabetes have been reported to have greater dyslipidemia after kidney transplant (KTX). Because postKTX management of diabetes has changed markedly since those reports, we hypothesized that lipids can be controlled as well in diabetic as in nondiabetic recipients. METHODS. We compared lipid levels up to 2 years after KTX (n=192) between diabetic and nondiabetic recipients. The cohort was subdivided into nondiabetic (nonDM-K; n=123), type 2 (DM2-K; n=33), or type 1 diabetes after KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22). RESULTS. Mean age and body mass index of DM2-K were greater than the others (P<0.01), and diabetes groups had a higher pretransplant A1C than nonDM-K (P<0.001). After KTX, lipid levels were not higher in diabetic than in nondiabetic recipients, and did not increase in any group. Total and low-density lipoprotein cholesterol levels decreased in DM1-K (P<0.001), high-density lipoprotein levels decreased in DM1-KP (P=0.02), and triglyceride levels were unchanged after KTX for all groups. A1C improved in DM1-K and DM1-KP (P<0.0001). There was less improvement in lipid levels with tacrolimus-sirolimus immunosuppression than with other steroid-containing regimens (P<0.05). CONCLUSIONS. Multiple mechanisms may contribute to better lipid levels in both groups as well as the lack of difference between diabetic and nondiabetic recipients compared with what has been reported previously: greater use of and more effective lipid-lowering agents, no significant weight gain, no difference in renal function between groups, and better control of glucose in the diabetic group. Thus, overall, lipids can be controlled as well in diabetic as in nondiabetic KTX recipients.

AB - BACKGROUND. Patients with diabetes have been reported to have greater dyslipidemia after kidney transplant (KTX). Because postKTX management of diabetes has changed markedly since those reports, we hypothesized that lipids can be controlled as well in diabetic as in nondiabetic recipients. METHODS. We compared lipid levels up to 2 years after KTX (n=192) between diabetic and nondiabetic recipients. The cohort was subdivided into nondiabetic (nonDM-K; n=123), type 2 (DM2-K; n=33), or type 1 diabetes after KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22). RESULTS. Mean age and body mass index of DM2-K were greater than the others (P<0.01), and diabetes groups had a higher pretransplant A1C than nonDM-K (P<0.001). After KTX, lipid levels were not higher in diabetic than in nondiabetic recipients, and did not increase in any group. Total and low-density lipoprotein cholesterol levels decreased in DM1-K (P<0.001), high-density lipoprotein levels decreased in DM1-KP (P=0.02), and triglyceride levels were unchanged after KTX for all groups. A1C improved in DM1-K and DM1-KP (P<0.0001). There was less improvement in lipid levels with tacrolimus-sirolimus immunosuppression than with other steroid-containing regimens (P<0.05). CONCLUSIONS. Multiple mechanisms may contribute to better lipid levels in both groups as well as the lack of difference between diabetic and nondiabetic recipients compared with what has been reported previously: greater use of and more effective lipid-lowering agents, no significant weight gain, no difference in renal function between groups, and better control of glucose in the diabetic group. Thus, overall, lipids can be controlled as well in diabetic as in nondiabetic KTX recipients.

KW - Diabetes

KW - Dyslipidemia

KW - Kidney Transplant

UR - http://www.scopus.com/inward/record.url?scp=43449136779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449136779&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31816de3F6

DO - 10.1097/TP.0b013e31816de3F6

M3 - Article

VL - 85

SP - 1270

EP - 1276

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -